– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14% of patients proceeded to transplant ...
- 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients with NPM1 or MLLr mutations; no discontinuations due to treatment-related adverse events - "The updated ...
– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% ...
WALTHAM, Mass., April 8, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the ...
– Favorable safety and tolerability profile; treatment discontinuations were low at 6% with none due to differentiation syndrome or QTc prolongation – – Supportive results from the AUGMENT-101 trial, ...
AUGMENT-101 is a Phase 1/2 open-label trial designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of orally administered revumenib. The Company previously announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results